TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02294357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: If the patient was receiving steroids at the equivalent of \> 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: If the patient was receiving steroids at the equivalent of \> 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: If the patient was receiving steroids at the equivalent of \> 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: f the patient was receiving prednisone, at the equivalent of \> 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: If the patient was receiving methylprednisolone at the equivalent of \> 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: administered PO at 4mg daily on days 1-21 of a 28 day cycle
Study: NCT01860599

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: 150 minutes of moderate exercise per week
Study: NCT04041921

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention

Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Grafting
Study: NCT01860599

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Without exercise
Description: Pre-study activity level (i.e. no exercise)
Study: NCT03520738

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples on an empty stomach

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples on an empty stomach

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples on an empty stomach

Intervention type: OTHER
Group type: OTHER
Intervention: Urinary samples
Description: first urinary in the morning
Study: NCT04041921

Intervention type: DRUG
Intervention: Medical treatment
Study: NCT00960804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: IV, 5 mg dose, q 8 weeks, for up to 80 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: IV, 10 mg dose, q 8 weeks, for up to 80 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV, q 8 weeks, for up to 80 weeks
Study: NCT04491461

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbal tea blend
Description: 1 cup of freshly brewed tea from an herbal tea blend.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Warm water
Description: 1 cup of warm water
Study: NCT00847418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine hydrochloride
Study: NCT01775423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Study: NCT03520738

Intervention type: OTHER
Group type: OTHER
Intervention: Urinary samples
Description: first urinary in the morning

Intervention type: OTHER
Group type: OTHER
Intervention: Urinary samples
Description: first urinary in the morning
Study: NCT02285296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized support program
Description: interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up
Study: NCT04486625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam-Avibactam
Description: 500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam-Avibactam
Description: 675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours
Study: NCT02422576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cinnamon extract
Description: acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lemon extract
Description: acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lemon extract plus eucalyptus extract
Description: acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thicken Up clear: TUC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thicken Up clear: TUC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thicken Up clear: TUC
Study: NCT01205022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02958605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone apps
Description: If already own a smartphone application dedicated to calculate medication dosage for children, the participant will be allowed to use his/her own application. Otherwise, the resident will be offered to chose among a list of applications paid by the research team (PediSafe, PediStat, Palm Pedi, Safedose, EZdrip peds). He/she will be instructed to practice with a few time at home before doing the simulations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handbook
Description: Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
Study: NCT02701881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long stenting using drug-eluting stent (Zilver PTX)
Description: Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spot stenting using drug-eluting stent (Zilver PTX)
Description: Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion
Study: NCT03744013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fortiva® 1mm
Description: Post mastectomy immediate reconstruction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fortiva® 1mm
Description: Post mastectomy immediate reconstruction
Study: NCT03576274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Enhanced Home Exercise (TEHE)
Description: A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.
Study: NCT03774615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol 30 mg (Feraccru®)
Description: Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
Study: NCT03404895

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Conventional Therapy
Description: Local wound care consists of at least once daily dressing Occasionally, a limited bedside debridement is indicated to excise small quantity of devitalized tissues and to provide better drainage. Antibiotic therapy including both gram-positive and gram-negative coverage when the DFU appears infected is guided by wound cultures and when necessary, Infectious Disease consultation. Debridement and amputation will be performed as clinically indicated. To promote healing after the more acute processes have been addressed, pressure offloading is frequently helpful in the healing of DFU. Pressure offloading treatment ranges from special dressings and devices to special diabetic foot wares. Offloading will be utilized as indicated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Local wound care consists of at least once daily dressing Occasionally, a limited bedside debridement is indicated to excise small quantity of devitalized tissues and to provide better drainage. Antibiotic therapy including both gram-positive and gram-negative coverage when the DFU appears infected is guided by wound cultures and when necessary, Infectious Disease consultation. Debridement and amputation will be performed as clinically indicated. To promote healing after the more acute processes have been addressed, pressure offloading is frequently helpful in the healing of DFU. Pressure offloading treatment ranges from special dressings and devices to special diabetic foot wares. Offloading will be utilized as indicated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venous Stent(s)
Description: After PVOO is confirmed by venography and IVUS, and patient subject is randomized to conventional therapy and stent placement, stent placement is performed immediately at the same sitting.
Study: NCT03576274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Enhanced Home Exercise (TEHE)
Description: A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Enhanced Home Exercise (TEHE)
Description: A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Auricular Point Acupressure (APA)
Description: A non invasive complementary method to provide pressure on the ear points.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure (APA)
Description: A non invasive complementary method to provide pressure on the ear points.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness body scan (MBI)
Description: The open, nonjudgmental attention to move one's attention calmly to the different part of the body
Study: NCT01517308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha 2a + ribavirin
Description: Comparison of different duration of drugs (48 weeks vs. 24 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a + ribavirin
Description: Comparison of different duration of drugs (48 weeks vs. 24 weeks)
Study: NCT03466047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein stomach
Description: encapsulated protein stomach

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein distal small intestine
Description: encapsulated protein distal small intestine
Study: NCT03249168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT02953015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manipulative articulatory (ART) and myofascial techniques
Description: Three manipulative articulatory (ART) and myofascial techniques will be performed to improve cervical and thoracic spine joint mobility and reducing soft tissue stiffness in the cervico-thoracic spine. ART technique is a low velocity to high amplitude technique where each joint is carried through its full motion to increase range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier. Myofascial technique is directed at the muscle and fascia treatment. It engages continual palpatory feedback to achieve release of myofascial tissues. During each treatment session, each technique will be carried out for 10 minutes including 2 minutes of resting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Transcutaneous Electrical Nerve Stimulation (TENS) of the upper trapezius muscle will be applied by a portable machine Master 932 (Elettronica Pagani SRL, Milan, Italy) that generates symmetric, bi-phasic rectangular pulses with 140μ sec duration. The current frequency will be set at 150 Hz and intensity will be increased up to patient's perception of paresthesia. The negative electrode will be placed on the active TrPs of the upper trapezius muscle and the positive one was on acromial tendon insertional site. The total duration of each application will be 20 minutes. Treatment frequency and duration will be the same of the EG treatment (1 session/week for 4 weeks). Each session will consist of 20 min of TENS and 10 min of resting in sitting position with the head lean on a pillow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (Prophylaxis therapy)
Description: Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA (Prophylaxis therapy)
Description: Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
Study: NCT03726073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical acupoint stimulation(TEAS) and auricular acupressure
Description: Bilaterally Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) will be used as the TEAS acupoints. Six acupoints (Shenmen, Point Zero, subcortex, heart, liver, and endocrine) located on ears will be used as the auricular acupressure points.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Patients in this group only receive usual care developed by the study hospital
Study: NCT03227393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga training
Description: Subjects will complete in class yoga training weekly for 8 weeks with additional practice at home
Study: NCT04301726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine Oral Tablet [Austedo]
Description: The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
Study: NCT03074604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aortic no-touch OPCABG
Description: (Study arm 1) In this intervention only the internal mammary artery grafts will be used (i.e. left internal mammary artery graft, right internal mammary artery graft, or a Y-graft that uses right internal mammary artery graft anastomosed onto left internal mammary artery graft to allow for a wide territory of myocardial revascularization). However, in the rare event that the aforementioned approach is insufficient to reach all target vessels, a reversed (great) saphenous vein graft may be used to extend the left internal mammary artery graft or the right internal mammary artery graft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OPCABG with partial clamp applying carbon dioxide
Description: (Study arm 2) In this intervention chest cavity will be insufflated with carbon dioxide at a flow above 5 l/min during the entire surgical procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OPCABG with partial clamp
Description: (Study arm 3) This is the control arm undergoing traditional OPCABG with partial clamp.
Study: NCT03012841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Advance Cardiac CryoAblation Catheter
Description: Cryoablation
Study: NCT02404402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LED
Description: Low Level Light Therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham LED
Description: Inactive (sham) LED treatment
Study: NCT02665819

Intervention type: OTHER
Intervention: Pediatric cancer women survivors
Description: Women will incur a blood taking to obtain fertility indication.
Study: NCT03102957

Intervention type: OTHER
Group type: OTHER
Intervention: functional MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional MRI
Study: NCT04646018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Spine Manipulation
Description: Lumbar non-thrust manipulation is a passive movement that is performed with a rhythm and a grade in a manner in which the patient is able to prevent the technique from being performed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: Lumbar non-thrust manipulation without force applied
Study: NCT04655781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: idiopathic macular hole (MH) surgery
Description: Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: idiopathic macular hole (MH) surgery
Description: Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns
Study: NCT06101186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPECP based on NSM
Description: A comprehensive training booklet which integrated NPECP and NSM principles was sent to five experts for their evaluation and feedback. Among these experts, one was a physician who specialized in obstetrics and gynecology while the remaining individuals were nurses. Group training sessions were conducted online, with each group comprising 4-6 participants. These sessions spanned four weeks, with each session being held weekly and lasting for approximately 60-90 minutes. The training covered various topics - including pregnancy, pregnancy-related changes, pregnancy danger signs, premature birth, stress, stress symptoms, stress coping strategies, childbirth, the postpartum period and the challenges of parenting (particularly when dealing with a pre-term baby)
Study: NCT01695005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally
Study: NCT03783117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic field treatment
Description: The MBPL device for clinical trials is made with modification of an electromagnet: A bore of 10cm diameter was made to go through the frame and poles. The device can produce a magnetic field close to 1.0 T inside the bore, which is along the axis direction. The trial for each subject takes about 20-30 minutes. To start with, the subject's blood pressure is measured first as the baseline. Afterwards, the subject places his/her right arm into the bore of the electromagnet for treatment while the blood pressure is monitored with the left arm. The magnetic treatment lasts about 15 minutes and will lower the subject's blood pressure. In order to see how long the effect lasts, the subject needs to return and measure the blood pressure again 24 hours after the treatment. The clinical trials are non-invasive. There is no medicine or surgery involved.
Study: NCT00052078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline (SRT)
Description: Participants were treated with sertraline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline (SRT)
Description: Participants were treated with sertraline.
Study: NCT03466047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHO stomach
Description: encapsulated CHO stomach

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHO distal small intestine
Description: encapsulated CHO distal small intestine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat stomach
Description: encapsulated Fat stomach

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat distal small intestine
Description: encapsulated Fat distal small intestine